Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study
Anthony R. Mato(Memorial Sloan Kettering Cancer Center), Michael Wang(St. Joseph Health System), Narasimha Marella(Loxo Oncology at Lilly (United States)), Manish R. Patel(Sarah Cannon), Jonathon B. Cohen(Emory University), Nicole Lamanna(Memorial Sloan Kettering Cancer Center), Jennifer A. Woyach(The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute), Minal Barve(Mary Crowley Cancer Research Center), Steven Le Gouill(Inserm), Jennifer R. Brown(Dana-Farber Cancer Institute), Catherine C. Coombs(Memorial Sloan Kettering Cancer Center), Suchitra Sundaram(Roswell Park Comprehensive Cancer Center), Katharine L. Lewis(Linear Clinical Research), Ewa Lech‐Marańda(Instytut Hematologii i Transfuzjologi), Omar Abdel‐Wahab(Memorial Sloan Kettering Cancer Center), Donald E. Tsai(University of Pennsylvania), Xuan Tan(Sir Charles Gairdner Hospital), Binoj C. Nair(Eli Lilly (United States)), Constantine S. Tam(The Alfred Hospital), James N. Gerson(UPMC Hillman Cancer Center), John M. Pagel(University of Washington), Ming Yin(Brigham and Women's Hospital), Lindsey E. Roeker(Memorial Sloan Kettering Cancer Center), M. Lia Palomba(Memorial Sloan Kettering Cancer Center), Toby A. Eyre(Oxford University Hospitals NHS Trust), Johan Wallin(Loxo Oncology at Lilly (United States)), Matthew S. Davids(Dana-Farber Cancer Institute), Chan Y. Cheah(The University of Western Australia), Timothy S. Fenske(Medical College of Wisconsin), Kevin Ebata(Memorial Sloan Kettering Cancer Center), Stephen J. Schuster(Hospital of the University of Pennsylvania), Bita Fakhri(University of California, San Francisco), Alvaro J. Alencar(University of Miami), Paolo Ghia(Vita-Salute San Raffaele University), Nirav N. Shah(Medical College of Wisconsin), Justin Taylor(Medical University of South Carolina), William G. Wierda(University of Maryland, Baltimore), Jessica Chen(Loxo Oncology at Lilly (United States)), Wojciech Jurczak(Jagiellonian University), David Lewis(University Hospitals Plymouth NHS Trust), Nora Ku(Loxo Oncology at Lilly (United States)), Ian W. Flinn(Tennessee Oncology), Edward Y. Zhu(Memorial Sloan Kettering Cancer Center), Bryone J. Kuss(Flinders Medical Centre)
Cited by 456
Related Papers
Leukemic IDH1 and IDH2 Mutations Result in a Hypermethylation Phenotype, Disrupt TET2 Function, and Impair Hematopoietic Differentiation
|Cancer Cell|2010|2.7k
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2013|2.2k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k